Interleukin-7 Reverses Lymphopenia and Improves T-Cell Function in Coronavirus Disease 2019 Patient With Inborn Error of Toll-Like Receptor 3: A Case Report
Authors:
Open Access
- 14 July 2021
- journal article
- case report
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 3 (7) , e0500
Abstract
BACKGROUND: Immunotherapy treatment for coronavirus disease 2019 combined with antiviral therapy and supportive care remains under intense investigation. However, the capacity to distinguish patients who would benefit from immunosuppressive or immune stimulatory therapies remains insufficient. Here, we present a patient with severe coronavirus disease 2019 with a defective immune response, treated successfully with interleukin-7 on compassionate basis with resultant improved adaptive immune function. CASE SUMMARY: A previously healthy 43-year-old male developed severe acute respiratory distress syndrome due to the severe acute respiratory syndrome coronavirus 2 virus with acute hypoxemic respiratory failure and persistent, profound lymphopenia. Functional analysis demonstrated depressed lymphocyte function and few antigen-specific T cells. Interleukin-7 administration resulted in reversal of lymphopenia and improved T-cell function. Respiratory function and clinical status rapidly improved, and he was discharged home. Whole exome sequencing identified a deleterious autosomal dominant mutation in TICAM1, associated with a dysfunctional type I interferon antiviral response with increased severity of coronavirus disease 2019 disease. CONCLUSIONS: Immunoadjuvant therapies to boost host immunity may be efficacious in life-threatening severe coronavirus disease 2019 infections, particularly by applying a precision medicine approach in selecting patients expressing an immunosuppressive phenotype.Keywords
This publication has 31 references indexed in Scilit:
- Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventionsAutoimmunity Reviews, 2020
- Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literatureCritical Care, 2020
- ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019*Critical Care Medicine, 2020
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, ItalyJAMA, 2020
- Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive studySignal Transduction and Targeted Therapy, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cellsCancer Immunology, Immunotherapy, 2016
- Harnessing the biology of IL-7 for therapeutic applicationNature Reviews Immunology, 2011
- A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunityProceedings of the National Academy of Sciences, 2008